公开(公告)号：US11485742B2

公开(公告)日：2022-11-01

申请号：US17065367

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US11919911B2

公开(公告)日：2024-03-05

申请号：US17346006

申请日：2021-06-11

Applicant: Novartis AG

Inventor： Sung David C. Kim ,  Zaixing Li ,  Chui Lu ,  Danuta Lubicka ,  James Neef ,  Hye-Yeon Park ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048 ,  C07D221/04

CPC classification number: C07D491/048 ,  C07D221/04 ,  C07B2200/13

Abstract: The present disclosure provides for a compound according to formula (I)




or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

公开(公告)号：US11453679B2

公开(公告)日：2022-09-27

申请号：US17345902

申请日：2021-06-11

Applicant: Novartis AG

Inventor： Thomas Charles Caya ,  James Neef ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.

公开(公告)号：US20210395261A1

公开(公告)日：2021-12-23

申请号：US17346006

申请日：2021-06-11

Applicant: Novartis AG

Inventor： Sung David C. Kim ,  Zaixing Li ,  Chui Lu ,  Danuta Lubicka ,  James Neef ,  Hye-Yeon Park ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048 ,  C07D221/04

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

公开(公告)号：US20250002499A1

公开(公告)日：2025-01-02

申请号：US18422517

申请日：2024-01-25

Applicant: Novartis AG

Inventor： Sung David C. Kim ,  Zaixing Li ,  Chui Lu ,  Danuta Lubicka ,  James Neef ,  Hye-Yeon Park ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048 ,  C07D221/04

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

公开(公告)号：US11820778B2

公开(公告)日：2023-11-21

申请号：US17818321

申请日：2022-08-08

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

CPC classification number: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US12122761B2

公开(公告)日：2024-10-22

申请号：US18062356

申请日：2022-12-06

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D401/04 ,  A61K45/06

CPC classification number: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US11548865B2

公开(公告)日：2023-01-10

申请号：US17065360

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20210387995A1

公开(公告)日：2021-12-16

申请号：US17345902

申请日：2021-06-11

Applicant: Novartis AG

Inventor： Thomas Charles Caya ,  James Neef ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.

公开(公告)号：US20180243297A1

公开(公告)日：2018-08-30

申请号：US15963535

申请日：2018-04-26

Applicant: Novartis AG

Inventor： Benjamin Richard Bellenie ,  Graham Charles Bloomfield ,  Ian Bruce ,  Andrew James Culshaw ,  Edward Charles Hall ,  Gregory John Hollingworth ,  James Neef ,  Matthew Spendiff ,  Simon James Watson

IPC: A61K31/497 ,  C07D413/14 ,  A61K31/5377 ,  C07D405/04 ,  C07D409/14 ,  C07D417/14 ,  C07D401/14 ,  C07D413/04 ,  C07D409/04 ,  C07D403/14 ,  C07D403/04 ,  C07D401/04 ,  C07D405/14 ,  C07D417/04

CPC classification number: A61K31/497 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.